Definitive Contract 75N92021C00012
Award Date
4/16/21
Potential Completion Date
7/31/24
Potential Value
$9.6M
Federal Agency
National Heart Lung and Blood Institute
Awardee
Ceres Nanosciences, Inc.
Ultimate Awardee
Not listed
NAICS Category
334516 - Analytical Laboratory Instrument Manufacturing
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Manassas, VA 20110, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
Ceres Nanosciences, Inc. was awarded a definitive contract valued at $6.57 million by the National Heart, Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to support the Rapid Acceleration of Diagnostics (RADx) initiative. The firm fixed price contract calls for Ceres Nanosciences to provide nanotrap particle manufacturing in Manassas, Virginia over a one year period ending August 2022. No subcontractors or set aside designations were identified. The RADx...
The U.S. Centers for Disease Control and Prevention (CDC) awarded a $78,048.30 firm fixed-price purchase order contract to Ceres Nanosciences, Inc., a for-profit organization based in Manassas, Virginia. The contract is for "Target-Capture Technology for Healthcare-Related Bacteria that are Prone to Carry Antimicrobial Resistant Genes." This award was not set aside. The contract has a period of performance through September 1, 2022. Ceres Nanosciences provides nanotechnology-enabled...
This firm fixed price purchase order from the Department of Health and Human Services (HHS) awards Biobot Analytics Inc. $1.94 million to provide COVID-19 wastewater data testing services. The contract supports HHS' Office of the Assistant Secretary for Administration under the Coronavirus COVID-19 national interest code. Per the solicitation, Biobot will collect and test samples from at least 320 wastewater treatment facilities serving over 100 million U.S. citizens across all 50 states and...
This is a firm fixed-price delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Cerba Research USA, Inc. for SARS-CoV-2 testing support. The total award value is $1,382,498.14, with a total ceiling of $1,615,094.14. The period of performance runs through December 31, 2023. This award is not associated with a larger contract vehicle, and no set-aside designation was used. Cerba...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $681,553.26 firm fixed-price definitive contract to Aquavitas, LLC, a for-profit limited liability company, for genomic sequencing of wastewater samples and analysis to detect the presence of the SARS-CoV-2 virus. The contract, which does not have a set-aside designation, has a completion date of February 14, 2022 and was awarded on September 24, 2021. The place of performance is Scottsdale, Arizona....
The Centers for Disease Control and Prevention awarded a $31 million firm fixed price contract to Biobot Analytics Inc. to provide commercial wastewater surveillance testing services in support of the National Wastewater Surveillance System. Under the terms of the contract, Biobot Analytics will quantitatively test wastewater samples twice weekly for SARS-CoV-2 and sequence qualifying samples over an 11-month period from April 2022 through February 2023. The contract is set aside for small...
This is a firm fixed price purchase order (contract) awarded by the Defense Health Agency to Biobot Analytics Inc., a self-certified small disadvantaged business, to provide SARS-COV-2 analytical services. The contract is valued at $129,600.00 and has a completion date of March 13, 2025. The original solicitation was set aside for total small business and required the contractor to provide ribonucleic acid (RNA) virus detection using quantitative polymerase chain reaction (qPCR) and reverse...
This $299,889 firm fixed price definitive contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Esper Biosciences Inc. for hepatitis C diagnostics using nanopore field-effect sensors. The contract is being performed in Ithaca, NY from September 2021 through September 2023. It falls under a Small Business Innovation Research solicitation issued by the NIH and Centers for Disease Control and Prevention seeking proposals for...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Heart Lung and Blood Institute awarded a $112,198.00 firm fixed price purchase order to Cerba Research USA Inc., a for-profit organization, to procure the services of BARC to assay serum biomarkers. The work is to be performed in Bethesda, Maryland and there are no set-aside designations or subcontractors indicated. Cerba Research USA Inc. is a clinical trial and laboratory services provider that...
The Centers for Disease Control and Prevention (CDC) awarded a $41,290,502.86 firm-fixed-price definitive contract to Verily Life Sciences LLC, doing business as G L S, for wastewater surveillance testing. The contract has an ultimate completion date of August 6, 2026 and was awarded on January 12, 2024 without any set-aside designation. Verily Life Sciences, a subsidiary of Alphabet Inc., specializes in collecting, organizing, and activating health data, and has provided wastewater surveillance...